Cargando…

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials

IMPORTANCE: An investigation of the treatment effect of lifitegrast ophthalmic solution, 5.0%, in different subgroups by severity of dry eye disease (DED) seems warranted. OBJECTIVE: To explore the heterogeneity across different subgroups of DED and identify which participants were most likely to ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holland, Edward J., Jackson, Mitchell A., Donnenfeld, Eric, Piccolo, Rebecca, Cohen, Alisa, Barabino, Stefano, Rolando, Maurizio, Figueiredo, Francisco C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498931/ https://www.ncbi.nlm.nih.gov/pubmed/34617974 http://dx.doi.org/10.1001/jamaophthalmol.2021.3943

Ejemplares similares

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

Dry Eye Disease: What Is the Role of Vitamin D?
por: Rolando, Maurizio, et al.
Publicado: (2023)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)

Dealing with the Persistent Pathogenic Issues of Dry Eye Disease: The Importance of External and Internal Stimuli and Tissue Responses
por: Rolando, Maurizio, et al.
Publicado: (2023)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease
por: Labetoulle, Marc, et al.
Publicado: (2022)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic
por: Barabino, Stefano
Publicado: (2021)

Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye
por: Nguyen, Theresa, et al.
Publicado: (2011)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
por: Shrivastava, Saurabh, et al.
Publicado: (2018)

Irrational ophthalmic fixed-dose combinations for dry eye syndrome
por: Kshirsagar, Nilima A, et al.
Publicado: (2022)

Is dry eye disease the same in young and old patients? A narrative review of the literature
por: Barabino, Stefano
Publicado: (2022)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh, Shizuka
Publicado: (2015)

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
por: Chung, Jou-Ku, et al.
Publicado: (2018)

Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
por: Epitropoulos, Alice T., et al.
Publicado: (2016)

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
por: Kashima, Tomoyuki, et al.
Publicado: (2014)

Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
por: Ueda, Kaori, et al.
Publicado: (2015)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
por: Du, Guoxin, et al.
Publicado: (2022)

The Management of Dry Eye Disease: Proceedings of Italian Dry Eye Consensus Group Using the Delphi Method
por: Aragona, Pasquale, et al.
Publicado: (2022)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

Special Issue “Managing Dry Eye Disease over Time: An Italian Consensus Conference”
por: Aragona, Pasquale, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r23jbgrb15v3vk7uepmhs43jeb